Antibodies that block CTLA-4 extrinsic and intrinsic immune regulation (ipilimumab, tremilimumab) result in clinical responses that correlate with the emergence of new high-avidity T cell clones and anti-tumor T cell clones [50, 51], suggesting that the site of action is in lymphoid tissue. Here, CTLA4 is linked to neoplasm.